Biography:
Katia Alves, MD, MPH, is a Senior Medical Director in Clinical Development with over 20 years of experience across all phases of clinical research. She has developed antivirals and vaccines, including SARS-CoV-2, and served as clinical trial lead for pivotal Phase 2/3 and Phase 3 studies supporting regulatory submissions and licensure, pre-IND applications, and Phase 1 studies. Dr. Alves has authored key protocols, clinical study reports, and more than 30 peer-reviewed publications. Her expertise spans vaccine safety, immunogenicity, and regulatory strategy, with a strong track record in leading large, multinational trials and cross-functional teams.
Title : Safety and immunogenicity of different antigen and adjuvant booster dose levels of protein-based Novavax COVID-19 vaccines in adults ≥50 years previously vaccinated with mRNA COVID-19 vaccines